ORIC Pharmaceuticals, Inc. (NasdaqGS: ORIC)
Health Care · Biotechnology · US
$11.78
-1.75% today · -13.8% 1Y
ORIC Pharmaceuticals, Inc. (NasdaqGS: ORIC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.24B and employs 111 people.
Over the last twelve months the share price has lost 13.8%, trading between 7.23 and 14.68.
Tweenvest scores ORIC Pharmaceuticals, Inc. across four factors: quality 39/100, value 90/100. Its strongest factor is value.
ORIC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.24B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.35
- Dividend yield
- —
- Beta (5Y)
- 0.98
- 52-week high
- $14.68
- 52-week low
- $7.23
- Avg volume (3M)
- —
- Shares outstanding
- 103.65M
- Employees
- 111
- Next earnings
- —
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
- ISIN
- US68622P1093
- Founded
- 2014
- Listed since
- Apr 24, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Seegene, Inc.KOSDAQ: A096530 | $1.29B | ₩38,150.00 | +3.39% |
| Replimune Group, Inc.NasdaqGS: REPL | $1.26B | $13.06 | -2.68% |
| Daan Gene Co., Ltd.SZSE: 002030 | $1.26B | CN¥6.03 | +4.87% |
| Savara Inc.NasdaqGS: SVRA | $1.25B | $4.88 | -0.91% |
| Suzhou Ribo Life Science Co., Ltd.SEHK: 6938 | $1.21B | HK$55.90 | +2.95% |
| Nanobiotix S.A.ENXTPA: NANO | $1.21B | €21.24 | +3.51% |
| Bio-Thera Solutions, Ltd.SHSE: 688177 | $1.19B | CN¥19.30 | -8.23% |
| BioGaia AB (publ)OM: BIOG B | $1.18B | Skr116.80 | +1.21% |
Figures last refreshed Oct 11, 2026.